Bacil Pharma Limited intimates BSE of a board meeting scheduled for May 22, 2026.
The board will consider approval of audited financial results for Q4 and FY ending March 31, 2026.
The intimation is made pursuant to SEBI LODR Regulations 29(1) and 30.